EyePoint rises after positive data from eye disease drug trial

EyePoint

28/10/2024 14:11

** Shares of EyePoint Pharmaceuticals  EYPT.O  rise 36.5% to
five-month high of $12.96
    ** Co says its drug, Duravyu, showed an improvement in how
well patients can see objects at a distance in a mid-stage trial
testing it in diabetic macular edema (DME)
    ** DME is an eye condition that causes blurry vision in
people with diabetes
    ** Co expects to report the full topline results in Q1 2025
    ** Including session's move, EYPT stock down 50.8% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))